Compare TWST & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | AXSM |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.5B |
| IPO Year | 2018 | 2015 |
| Metric | TWST | AXSM |
|---|---|---|
| Price | $110.22 | $135.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 22 |
| Target Price | $128.92 | ★ $264.62 |
| AVG Volume (30 Days) | ★ 2.3M | 1.0M |
| Earning Date | 11-12-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $459,433,000.00 | N/A |
| Revenue This Year | $21.02 | $49.25 |
| Revenue Next Year | $18.75 | $52.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.00 | N/A |
| 52 Week Low | $25.23 | $123.00 |
| 52 Week High | $219.71 | $260.19 |
| Indicator | TWST | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 36.03 |
| Support Level | $79.90 | $123.00 |
| Resistance Level | $155.44 | $225.16 |
| Average True Range (ATR) | 15.07 | 7.85 |
| MACD | -3.22 | 1.71 |
| Stochastic Oscillator | 18.52 | 42.78 |
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.